Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
DEK
REST API REST API
Homo sapiens
DEK is differentially expressed in 285 experiments: 101 organism parts: liver, amygdala, ... (99 more);, 163 disease states: normal, acute myeloid leukemia, ... (161 more);, 80 cell types 282 cell lines 28 compound treatments and 74 other conditions.
Synonyms D6S231E
Orthologs Q5F422_CHICK (Gallus gallus)   ENSCING00000010564 (Ciona intestinalis)   Dek (Rattus norvegicus)   A5PJQ1_BOVIN (Bos taurus)   DEK (Danio rerio)   Dek (Mus musculus)   Dek (Drosophila melanogaster)   dek (Xenopus laevis)   XM_848066.1 (Canis familiaris)   XM_857966.1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, histone binding, nucleic acid binding, transcription from RNA polymerase II promoter, nucleus, chromatin modification, regulation of transcription from RNA polymerase II promoter, signal transduction, viral genome replication
InterPro Term DEK_C, SAP_DNA-bd
UniProt Accession D6R9L5, P35659, D6RDA2, Q6MZJ9, B4DN37, B4DFG0
Search EB-eye ENSG00000124795
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-MEXP-1251, E-MTAB-24, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (39 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-GEOD-24147, E-MTAB-37
Raji
2
E-MTAB-37, E-GEOD-96
A549
1
2
E-GEOD-3202, E-GEOD-6013
MCF-7
2
E-GEOD-19639, E-GEOD-20081
MDA-MB-231
2
E-TABM-420, E-MTAB-62
MDA468
2
E-MEXP-440, E-MTAB-62
276 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-3920, E-MEXP-750, E-GEOD-13909, E-GEOD-20677, ... (39 experiments)

Factor Value U/D Experiments
stromal cell
2
E-MEXP-2034, E-GEOD-10797
memory B cell
2
E-MEXP-2360, E-TABM-702
liver cancer
1
E-GEOD-21154
CD19+ B cells (neg. sel.)
1
1
E-AFMX-5
iPSC derived from hASC using lentiviral reprogramming vector
1
E-GEOD-20033
LCC
1
E-GEOD-19188
74 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-4060, E-MTAB-62, E-MTAB-680, ... (57 experiments)

Factor Value U/D Experiments
chronic lymphocytic leukemia
2
E-GEOD-6691, E-GEOD-2466
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
glioblastoma
2
E-GEOD-6014, E-GEOD-4290
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
embryonal rhabdomyosarcoma
1
E-MTAB-62
breast cancer, adenovirus expressing GFP
1
E-MTAB-62
157 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5741, E-GEOD-15205, E-GEOD-1417, E-TABM-782, ... (22 experiments)

Factor Value U/D Experiments
none
3
6
E-GEOD-5824, E-TABM-782, E-GEOD-2803, E-GEOD-412, E-MEXP-1958, ... (9 experiments)
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
control for heregulin
1
E-GEOD-6462
phorbol 12-myristate 13-acetate + ionomycin
1
E-GEOD-3720
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
vanadium pentoxide
1
E-GEOD-5339
22 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-2191, E-GEOD-2034, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-4667, E-MEXP-958, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-1751, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-GEOD-18005, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-127, E-GEOD-20504, E-MEXP-1446, E-GEOD-22278, E-GEOD-19018, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (37 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980, E-GEOD-360 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, ... (8 experiments)

Population
studied in E-MTAB-197, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-1703, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-1561, E-GEOD-4922, ... (6 experiments)

Processing time: 0.326 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM